Portal de Periódicos da CAPES

Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors

2020; Elsevier BV; Volume: 65; Issue: 2 Linguagem: Inglês

10.1016/j.advms.2020.06.002

1898-4002

Bartosz Puła, Monika Długosz‐Danecka, Aleksander Salomon‐Perzyński, Agnieszka Szymczyk, Edyta Subocz, Bożena Katarzyna Budziszewska, Justyna Rybka, Lidia Gil, Anna Waszczuk‐Gajda, Elżbieta Iskierka‐Jażdżewska, Jan Maciej Zaucha, Michał Osowiecki, Weronika Piszczek, Paweł Steckiewicz, Łukasz Szukalski, Marek Hus, Ewa Lech‐Marańda, Wojciech Jurczak, Krzysztof Jamroziak,

Advanced Breast Cancer Therapies

High-dose methylprednisolone (HDMP) with or without anti-CD20 antibody treatment in the pre B-cell receptor inhibitor (BCRi) era was used as potential salvage therapy for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL) patients bearing the 17p deletion. Outcomes were compared in retrospect between r/r patients treated with HDMP (n = 20), ibrutinib (n = 39) and idelalisib with rituximab (n = 14). Higher overall response rates were found in those patients undergoing BCRi therapy compared to HDMP (79.2% vs. 0%; p < 0.0001), along with longer median progression-free survival (not reached vs. 24.1 months; p < 0.01). Nevertheless, there were no differences in the overall survival (HDMP 35.87 months vs. not reached; p = 0.58). HDMP treatment was significantly inferior in terms of response rate and progression-free survival in r/r CLL/SLL patients with the 17p deletion, and may only be used whenever novel compounds are unavailable.